Scancell Hldgs Plc

Zephyr Energy has lined up non-dilutive financing of up to $15 million for its Paradox Basin project in Utah, with Atlas Oil Company set to be repaid purely from future production, and no shares will be issued or working interest sold. Quantum Blockchain Technologies received US approval for a patent application covering technology to cut redundant calculations in Bitcoin mining hardware and will explore licensing deals with established ASIC manufacturers. Pathos Communications expects first-half revenue to jump 14% to $7.3 million and adjusted EBITDA to rise 31%, as its AI platform and new sales structure drive a roughly 30% increase in monthly client sign-ups and more than double repeat customers. AOTI reported underlying first-half revenue growth of 18%, ahead of full-year guidance, with Veterans Administration demand bouncing back strongly, and said proposed nationwide Medicare coverage for its wound-care technology could be transformative once finalized. Scancell Holdings confirmed its UK fundraise raised £15.7 million, with the retail offer upsized after strong demand, and the money will help fund a global phase III trial of its melanoma treatment alongside its merger with US biotech Neuphoria.

Neuphoria Therapeutics confirmed it is in discussions with London-listed Scancell Holdings about a potential acquisition of Neuphoria by Scancell, with Scancell becoming a Nasdaq-listed company after any deal. The statement follows an earlier announcement by Scancell about a possible combination, made after UK press speculation and in compliance with UK regulations. Neuphoria cautioned that there is no certainty an agreement will be reached, nor on the terms or whether a transaction will proceed. Any further announcements will be made in line with SEC and Nasdaq rules.